KPV vs VIP (Vasoactive Intestinal Peptide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
KPV
KPV is a tripeptide (Lys-Pro-Val) derived from alpha-melanocyte-stimulating hormone (α-MSH). It retains the potent anti-inflammatory properties of the parent hormone without the tanning or other melanocortin effects.
Full details →VIP (Vasoactive Intestinal Peptide)
VIP is a 28-amino acid neuropeptide with wide-ranging effects throughout the body. It acts as a neurotransmitter, neuromodulator, and immune regulator with particular importance in gut and lung function.
Full details →Side-by-Side Comparison
| Aspect | KPV | VIP (Vasoactive Intestinal Peptide) |
|---|---|---|
| Dose Range | 200 mcg–500 mcg | 100 mcg–200 mcg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 4–8 weeks | 2–8 weeks |
| Route | subcutaneous | intranasal |
| Mechanism | Inhibits NF-κB activation and reduces inflammatory cytokine production. Enters cells and directly modulates inflammatory signaling without requiring melanocortin receptors. | Binds to VPAC1 and VPAC2 receptors to modulate immune responses, regulate circadian rhythms, promote vasodilation, and support barrier function in gut and lungs. Has potent anti-inflammatory effects. |
| Typical Dosage | Oral/sublingual: 200-500mcg 1-3 times daily. Topical formulations for localized inflammation. Also used in enemas for gut inflammation. | Intranasal: 50-200mcg 1-3 times daily for chronic inflammatory conditions. Some protocols use subcutaneous administration. Dosing varies by condition. |
| Administration | Can be taken orally, sublingually, or as suppositories/enemas for gut inflammation. Topical use for skin conditions. Stable orally unlike most peptides. | Intranasal is most common for inflammatory conditions. Subcutaneous injection also used. Must be stored cold and protected from light. |
| Side Effects | Generally very well-tolerated. Minimal systemic effects due to targeted anti-inflammatory action. | May cause nasal irritation, flushing, headache, or temporary diarrhea. Generally well-tolerated at standard doses. |
| Best For |
What They Have in Common
KPV, VIP (Vasoactive Intestinal Peptide) are both commonly used for:
Key Differences
Unique to KPV:
Unique to VIP (Vasoactive Intestinal Peptide):
Which Has Stronger Evidence?
| Goal | KPV | VIP (Vasoactive Intestinal Peptide) |
|---|---|---|
| Gut Health | medium | medium |
Key Studies
KPV
- KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signaling.
Tissue & cell, 2026
- KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy.
Advanced healthcare materials, 2024
- A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon.
Acta biomaterialia, 2022
VIP (Vasoactive Intestinal Peptide)
- Distribution of vasoactive intestinal peptide (VIP) immunoreactivity in the rat pallial and subpallial amygdala and colocalization with γ-aminobutyric acid (GABA).
Anatomical record (Hoboken, N.J. : 2007), 2024
- Increased Vasoactive Intestinal Peptide (VIP) in polycystic ovary syndrome patients undergoing IVF.
Frontiers in endocrinology, 2024
- Therapeutic Potential of Vasoactive Intestinal Peptide and its Derivative Stearyl-Norleucine-VIP in Inflammation-Induced Osteolysis.
Frontiers in pharmacology, 2021
Ready to Learn More?
Looking for trusted sources?